In folder labeled Kennedy, Wm thereis a report entitled “Response of Human Bone
Marrow Cells to Timed Exposure of Erythropoietin ‘in vitro.’”
oi
On page 2, there is a
comment “EPO: Humanurinary erythropoietin was generously supplied by Dr. JosephF.
Garcia of the Lawrence Berkeley Laboratory, Berkeley, CA.”
In folder labeled LINFOOT,Dr.J.A. there is a chronicling of Dr. Linfoot’s dismissal from
LBLfor insubordination,specifically for referring follow-ups of Donnerpatients to the
Alta Bates Center and using Donnerpatient records outside of his employmentat
Donner Lab.
In folder labeled HUMAN USE COMM... LBLthereis a list of members of the LBL
Human Use Committee for 1981 (Born - died 10/81; Siri retired; new members:
Schimmerling and Ms.Kathleen E. Handron; Dr. Henry H. Stauffer was named
Chairmanof the Committee.) Members of the LBL Radioactive Drug Research
Committee: (Born - died 10/81; new member: Dr. Stephen B. Lewis; Dr. Fabrikant
named Chairmanof the Committee.
There is also a note to Miss Jan DeMoor, Executive Officer of the LBL Human Use
Committee dated October 30, 1981 describing a collaborative study with Dr. Bert Lubin
of Children’s Hospital Medical Center of Northern California, Oakland to study
lipoproteins in cord blood (approved by the Alta Bates Human Use Committee in
August, 1981) Trudy Forte and Alpen (authors of note) state: “we have had no
problemsin obtaining and processing the samples.”
Also there is a Memo dated September 25, 1981 from Alpen to the Bio-Med
Scientific Staff RE: Research Involving Human Subjects. This remindsall investigators
that any project at LBL whether DOE, NIH,or other source, which will in any way
involve human subjects must be approved by the LBL Human Use Committee and the
Campus Committee for Protection of Human Subjects priorto initiation of research.
{Photocopied this document}.
Box 6 of 6: In folder titled ABRA Director’s Review 9/10 -11/84 there is a review (and
supporting documentation and correspondence) of a proposedinitiative for research
into the biomedical applications of charged particle beams, including the construction of
an Advanced Biomedical Research Accelerator (ABRA). The review was requested by
Dr. D.A. Shirley, Director of Lawrence Berkeley Laboratory.